Only for the use of Medical Professionals
Paricel® is a preparation of Rabeprazole Sodium. It is an antisecretory compound that suppresses
gastric acid secretion by inhibiting the gastric H+, K+ ATPase at the secretory surface of the gastric
Healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD)
Maintenance of healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD)
Prevention of Relapse of Gastro-Esophageal Reflux Disease (GERD)
Treatment of Symptomatic Gastro-Esophageal Reflux Disease (GERD)
Healing of Duodenal & Gastric Ulcers
Helicobacter pylori eradication to reduce the risk of Duodenal & Gastric Ulcer Recurrence
Treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome
Dosage and administration
Healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The
recommended adult oral dose is Paricel® 20 mg to be taken once daily for 4 to 8 weeks. For those
patients who have not healed after 8 weeks of treatment, an additional 8 weeks course of Paricel®
20 mg may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastro-Esophageal Reflux Disease
(GERD): The recommended adult oral dose is Paricel® 20 mg to be taken once daily.
Prevention of Relapse of Gastro-Esophageal Reflux Disease (GERD): The recommended adult oral
dose is Paricel® 10 mg to be taken once daily. If needed this dose should be increased to Paricel®
20 mg to be taken once daily.
Treatment of Symptomatic Gastro-Esophageal Reflux Disease (GERD): The recommended
adult oral dose is Paricel® 20 mg to be taken once daily for 4 weeks. If symptoms do not resolve
completely after 4 weeks, an additional course of treatment may be considered.
Treatment should commence at Paricel® 10 mg once daily in patients without esophagitis. If there
is no response, the dose should be increased to 20 mg once daily for four weeks. If symptoms do
not resolve completely after 4 weeks, the patient should be further investigated.
Once symptoms have resolved, subsequent symptom control can be achieved using an on demand
regimen of 10 mg to be taken once daily, when needed.
Healing of Duodenal Ulcers and Gastric Ulcers: The recommended adult oral dose for both
duodenal ulcer and gastric ulcer is Paricel® 20 mg to be taken once daily for a period up to 4
weeks. Most patients with duodenal ulcer heal within 4 weeks.
Some patients with duodenal ulcer may respond to Paricel® 10 mg once daily. A few patients may
require additional therapy to achieve healing.
Most patients with gastric ulcer heal within 6 weeks. However, again a few patients may require an
additional 6 weeks of therapy to achieve healing.
Helicobacter pylori eradication to reduce the risk of Duodenal or Gastric Ulcer
Recurrence: Most patients with gastro-duodenal ulcer or chronic gastritis due to H. pylori infection
should be treated with three drug regimenRabeprazole 20 mg Twice daily for 7 days
Amoxycillin 1000 mg Twice daily for 7 days
Clarithromycin 500 mg Twice daily for 7 days
All three medications should be taken twice daily with the morning and evening meals.
Treatment of pathological hypersecretory conditions including Zollinger-Ellison
Syndrome: The recommended adult oral starting dose is 60 mg once daily. Doses should be
adjusted to individual patient needs and should continue for as long as clinically indicated. Some
patients may require divided doses. Doses up to 100 mg once daily and 60 mg BID have been
Treatment of GERD in Pediatric Patients 1 to 11 years of age: The recommended dosage of
Paricel® for pediatric patients 1 to 11 years of age by body weight is:
15 kg or more: 10 mg once daily for up to 12 weeks.
Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if
there is inadequate response.
Use in children
Paricel® is indicated for treatment of GERD in children 1 to 11 years of age for up to 12 weeks.
Use in elderly
No dosage adjustment is necessary in elderly patients. No overall differences in safety and
effectiveness were observed between these subjects or younger subjects, and other reported
clinical experience has not identified differences between the elderly and younger patients.
Use in patients with hepatic & renal impairment
No dosage adjustment is necessary in patients with renal impairment or mild to moderate hepatic
impairment. There is no information in patients with severe hepatic impairment. Avoid use of
Rabeprazole in patients with severe hepatic impairment; however, if treatment is necessary,
monitor patients for adverse reactions.
Use in pregnancy & lactation
No evidence of adverse developmental effects were seen in animal reproduction studies with
Rabeprazole administered during organogenesis at 13 and 8 times the human area under the
plasma concentration-time curve (AUC) at the recommended dose for GERD, in rats and rabbits,
respectively. There are no available human data on Rabeprazole use in pregnant women to inform
the drug associated risk and this drug should be used during pregnancy only if clearly needed.
Rabeprazole is excreted in rat milk. Caution should be exercised when Rabeprazole is administered
to a lactating woman.
Most common adverse reactions in adults are pain, pharyngitis, flatulence, infection & constipation
and most common adverse reactions in adolescents are headache, diarrhea, nausea, vomiting, and
Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, substituted
benzimidazoles or to any component of the formulation.
Symptomatic response to therapy with Rabeprazole does not prelude the response of gastric
malignancy. There have been reports of increased International Normalized Ratio (INR) and
Prothrombin Time (PT) in patients receiving a proton pump inhibitor and Warfarin concomitantly.
Patients treated with a proton pump inhibitor and Warfarin concomitantly may need to monitor for
increase in INR and prothrombin time.
Rabeprazole produces a profound and long lasting inhibition of gastric acid secretion. An interaction
with compounds whose absorption is pH dependent may occur. Co-administration of Rabeprazole
with Ketoconazole or Itraconazole may result in a significant decrease in antifungal plasma levels.
Therefore individual patients may need to be monitored to determine if a dosage adjustment is
necessary when Ketoconazole or Itraconazole are taken concomitantly with Rabeprazole.
In clinical trials, antacids were used concomitantly with the administration of Rabeprazole and, in
a specific drug-drug interaction study, no interaction with liquid antacids was observed.
Co-administration of Atazanavir 300 mg/Ritonavir 100 mg with Omeprazole (40 mg once daily) or
Atazanavir 400 mg with Lansoprazole (60 mg once daily) to healthy volunteers resulted in a
substantial reduction in Atazanavir exposure. The absorption of Atazanavir is pH dependent.
Although not studied, similar results are expected with other proton pump inhibitors. Therefore
PPIs, including Rabeprazole, should not be co-administered with Atazanavir.
Concomitant administration of PPIs and Methotrexate (primarily at high dose) may elevate and
prolong serum levels of Methotrexate and/or its metabolite Hydroxymethotrexate. However, no
formal drug interaction studies of Methotrexate with PPIs have been conducted.
There has been no experience with large overdoses with Rabeprazole. No specific antidote for
Rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In
the event of over dosage treatment should be symptomatic and supportive.
Store below 25oC. Protect from light & moisture.
Paricel® 10 Tablet : Each enteric coated tablet contains Rabeprazole Sodium INN 10 mg.
Paricel® 20 Tablet : Each enteric coated tablet contains Rabeprazole Sodium INN 20 mg.
Paricel® 20 Capsule : Each HPMC shell capsule contains Rabeprazole Sodium INN 20 mg as enteric
Paricel® 10 Tablet : Carton of 60 tablets is available in 4 alu-alu sachets and each sachet contains
15 tablets in alu-alu blister strip.
Paricel® 20 Tablet : Carton of 100 tablets is available in 10 alu-alu sachets and each sachet
contains 10 tablets in alu-alu blister strip.
Paricel® 20 Capsule : Carton of 50 capsules is available in 5 alu-alu sachets and each sachet
contains 10 capsules in alu-alu blister strip.
® Registered Trade Mark
Brand: ACI Limited.